See more : Lunit Inc. (328130.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of TSH Biopharm Corporation Limited (8432.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TSH Biopharm Corporation Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- National Graphite Corp. (NGRC) Income Statement Analysis – Financial Results
- Champion Iron Limited (CIA.TO) Income Statement Analysis – Financial Results
- Absolute Software Corporation (ABST.TO) Income Statement Analysis – Financial Results
- NextGen Acquisition Corp. II (NGCAU) Income Statement Analysis – Financial Results
- Bharat Dynamics Limited (BDL.BO) Income Statement Analysis – Financial Results
TSH Biopharm Corporation Limited (8432.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.tshbiopharm.com
About TSH Biopharm Corporation Limited
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan and Asia. It offers products for cardiovascular, central nervous, gastrointestinal, and others. The company was founded in 1999 and is headquartered in Taipei city, Taiwan. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 810.92M | 741.07M | 413.48M | 447.86M | 507.67M |
| Cost of Revenue | 411.02M | 351.20M | 166.13M | 162.67M | 202.55M |
| Gross Profit | 399.90M | 389.87M | 247.36M | 285.19M | 305.12M |
| Gross Profit Ratio | 49.31% | 52.61% | 59.82% | 63.68% | 60.10% |
| Research & Development | 24.81M | 31.09M | 23.52M | 28.68M | 51.79M |
| General & Administrative | 97.66M | 93.10M | 48.11M | 57.47M | 0.00 |
| Selling & Marketing | 215.73M | 196.62M | 120.22M | 124.84M | 0.00 |
| SG&A | 313.39M | 289.71M | 168.33M | 182.31M | 197.13M |
| Other Expenses | 0.00 | 12.58M | 3.92M | 717.00K | 0.00 |
| Operating Expenses | 336.27M | 320.81M | 191.84M | 210.99M | 248.92M |
| Cost & Expenses | 747.29M | 672.00M | 357.97M | 373.66M | 451.47M |
| Interest Income | 6.60M | 3.33M | 2.10M | 2.24M | 2.84M |
| Interest Expense | 688.00K | 699.00K | 80.00K | 27.00K | 82.00K |
| Depreciation & Amortization | 22.57M | 21.53M | 9.79M | 9.65M | 9.61M |
| EBITDA | 99.35M | 106.51M | 71.31M | 86.81M | 113.05M |
| EBITDA Ratio | 12.25% | 14.37% | 17.25% | 19.38% | 22.27% |
| Operating Income | 63.63M | 84.98M | 61.53M | 77.16M | 56.20M |
| Operating Income Ratio | 7.85% | 11.47% | 14.88% | 17.23% | 11.07% |
| Total Other Income/Expenses | 12.46M | -3.74M | 5.93M | 76.00K | 47.16M |
| Income Before Tax | 76.09M | 81.24M | 61.55M | 77.23M | 103.36M |
| Income Before Tax Ratio | 9.38% | 10.96% | 14.89% | 17.24% | 20.36% |
| Income Tax Expense | 11.11M | 15.10M | 14.44M | 15.66M | 18.03M |
| Net Income | 61.99M | 61.89M | 47.11M | 61.57M | 85.33M |
| Net Income Ratio | 7.64% | 8.35% | 11.39% | 13.75% | 16.81% |
| EPS | 1.61 | 1.61 | 1.23 | 1.60 | 2.22 |
| EPS Diluted | 1.61 | 1.61 | 1.23 | 1.60 | 2.22 |
| Weighted Avg Shares Out | 38.40M | 38.40M | 38.30M | 38.40M | 38.40M |
| Weighted Avg Shares Out (Dil) | 38.43M | 38.45M | 38.30M | 38.43M | 38.43M |
Source: https://incomestatements.info
Category: Stock Reports